Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A408R7 | ISIN: US54303L2034 | Ticker-Symbol:
NASDAQ
06.06.25 | 20:28
1,220 US-Dollar
+3,39 % +0,040
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
LONGEVERON INC Chart 1 Jahr
5-Tage-Chart
LONGEVERON INC 5-Tage-Chart

Aktuelle News zur LONGEVERON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.05.Longeveron to Attend BIO International Convention 20257
12.05.Longeveron Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient3
08.05.Longeveron Q1 2025 slides: promising clinical data amid financial headwinds1
08.05.Longeveron Inc. - 8-K, Current Report1
08.05.Longeveron Announces First Quarter 2025 Financial Results and Provides Business Update81Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to...
► Artikel lesen
08.05.Longeveron Inc. - 10-Q, Quarterly Report3
LONGEVERON Aktie jetzt für 0€ handeln
28.03.Longeveron files $70M mixed securities shelf1
20.03.Longeveron Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease228Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer's diseaseAlignment with FDA on proposed trial study design...
► Artikel lesen
14.03.Longeveron Inc. - 8-K, Current Report2
11.03.Longeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B) in Alzheimer's Disease203Phase 2a results demonstrated laromestrocel (Lomecel-B) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's diseaseThis encouraging clinical trial data...
► Artikel lesen
03.03.Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript1
28.02.Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update326Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more...
► Artikel lesen
28.02.Longeveron Inc. - 8-K, Current Report-
28.02.Longeveron Inc. - 10-K, Annual Report-
18.02.Longeveron Announces World Health Organization Approval of "laromestrocel" as International Non-proprietary Name for Stem Cell Therapy Lomecel-B1
30.01.Longeveron Inc. - 8-K, Current Report-
18.12.24Longeveron to Present at Biotech Showcase 20253
27.10.24Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting157Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none...
► Artikel lesen
10.07.24Pre-market Movers: VivoPower, NaaS Technology, Ampco-Pittsburgh, LegalZoom.com, Longeveron878OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.15 A.M. ET).In the Green VivoPower International PLC (VVPR) is up over 90%...
► Artikel lesen
10.07.24Longeveron Announces U.S. FDA Grants Lomecel-B Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease615MIAMI, July 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for certain life-threatening and...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1